Yashvin Onkarappa Mangala, MD
Internal Medicine · Providence, RINPI 1184100992
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,876 of the $6,746 with a category attached, or 87.1%. It is spread thinly across 40 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,737, 2.7 times the $639 reported in 2019. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $49.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Incyte Corporation$731
- AstraZeneca$384
- Pfizer$382
- Gilead$365
- Janssen Scientific Affairs, LLC$354
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,87687%
- Education$87113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 23 | $1,197 |
| Incyte Corporation | 9 | $731 |
| AstraZeneca(2 entities) | 10 | $384 |
| Pfizer | 4 | $382 |
| Gilead(2 entities) | 6 | $365 |
| Janssen Scientific Affairs, LLC | 5 | $354 |
| E.r. Squibb & Sons, L.L.C. | 9 | $334 |
| ADC Therapeutics America, Inc. | 2 | $256 |
| Eisai Inc. | 6 | $224 |
| Amgen | 2 | $199 |
| Bristol Myers Squibb | 4 | $196 |
| AbbVie | 2 | $184 |
| Sanofi | 3 | $171 |
| Rigel Pharmaceuticals, Inc. | 1 | $124 |
| Radius Health, Inc. | 1 | $123 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $122 |
| Pharmacosmos Therapeutics Inc. | 2 | $121 |
| Tempus AI, Inc | 1 | $116 |
| Mirati Therapeutics, Inc. | 1 | $112 |
| Astellas Pharma US Inc | 3 | $109 |
| Novartis | 5 | $107 |
| Seagen Inc. | 1 | $102 |
| Bayer | 6 | $102 |
| Array Biopharma Inc | 5 | $100 |
| Daiichi Sankyo Inc. | 4 | $89 |
| Sobi, Inc | 2 | $58 |
| Beone Medicines USA, Inc. | 3 | $56 |
| AVEO Pharmaceuticals, Inc. | 2 | $55 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Springworks Therapeutics, Inc. | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Puma Biotechnology, Inc. | 1 | $28 |
| Genmab U.S., Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Exelixis Inc. | 1 | $22 |
| Legend Biotech USA Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Beigene USA, Inc. | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,746 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 15 | $32,662 |
| EliquisApixaban | 14 | $9,339 |
| Imatinib Mesylate | 13 | $1,076 |
| Prochlorperazine Maleate | 24 | $475 |
| Anastrozole | 27 | $413 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $257 |
| Dexamethasone | 12 | $254 |
| Ondansetron Hcl | 13 | $155 |
| Prednisone | 22 | $145 |
| Potassium Chloride | 11 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $354 | $32,66215 claims |
| PfizerEliquis | $382 | $9,33914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Providence
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Brian McCauleyProvidence$20K
- Meghan NahassProvidence$19K
- William LangProvidence$15K
- Abdelmoniem MoustafaProvidence$13K
- Khushal ChoudharyProvidence$10K
- Kenneth ChenProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.